Tonix Pharmaceuticals stock halted ahead of FDA approval news
Idacorp Inc’s stock reached an all-time high of 126.71 USD, marking a significant milestone for the company. According to InvestingPro data, the stock is currently trading near its 52-week high with notably low price volatility, a characteristic that may appeal to conservative investors. This surge reflects a robust performance over the past year, with the stock delivering a 27% total return. The company maintains a solid 2.74% dividend yield and has maintained dividend payments for an impressive 55 consecutive years. The company’s consistent growth and strategic initiatives have contributed to this upward trajectory, attracting investor confidence and interest. While analyst targets range from $120 to $140, InvestingPro analysis suggests the stock may be overvalued at current levels. As Idacorp continues to expand its operations and optimize its services, investors can access detailed valuation metrics and 8 additional ProTips through InvestingPro’s comprehensive research reports.
In other recent news, IDACORP Inc. reported earnings for the second quarter of 2025 that exceeded analysts’ expectations. The company’s earnings per share reached $1.76, surpassing the forecast of $1.73. Additionally, IDACORP reported revenue of $531.1 million, which was higher than the anticipated $478.14 million, marking a revenue surprise of 11.08%. These results led the company to raise its guidance for the year. The earnings announcement was followed by a slight increase in the company’s stock during regular trading hours. While specific stock price movements are not the focus, the positive earnings and revenue results are noteworthy for investors. The company’s performance is being closely watched by analysts and investors alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.